← Back to Clinical Trials
Recruiting Phase 2 NCT06375083

NCT06375083 Computerized Cognitive Behavioral Therapies for Suicide Prevention and Depression

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06375083
Status Recruiting
Phase Phase 2
Sponsor VA Eastern Colorado Health Care System
Condition Suicide
Study Type INTERVENTIONAL
Enrollment 472 participants
Start Date 2024-03-20
Primary Completion 2026-08-30

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 65 Years
Study Type INTERVENTIONAL
All Conditions
Interventions
c-CBT for Suicide Preventionc-CBT or Depression

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.

This trial targets 472 participants in total. It began in 2024-03-20 with a primary completion date of 2026-08-30.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This study plans to learn more about the use of one of two self-guided online cognitive behavioral therapy courses. One is focused on symptoms of depression and one is focused on history of suicidal thoughts and behaviors.

Eligibility Criteria

Cohort A - cCBT-SP Program Inclusion Criteria: 1. Veterans between the ages of 18 and 65 2. Currently living in Colorado, New York, Montana, Texas, or Utah who have accessed VA Care 3. Recent suicidal ideation (past month; C-SSRS Screener -Yes to Item 2) and history of lifetime suicidal behavior (lifetime, C-SSRS Screener - Yes to Item 6) 4. Reliable access to a computer/tablet and the internet 5. Ability to provide informed consent Exclusion Criteria: 1. Active alcohol or substance use disorder, excluding Cannabis dependence, as determined by screening or electronic medical record 2. Identification of active psychosis or bipolar disorder, as determined via screening or electronic medical record 3. Severe cognitive impairment, as determined by screening or electronic medical record 4. Currently enrolled in/participating in another mental health-related intervention research study Cohort B - cCBT-D Program Inclusion Criteria: 1. Veterans between the ages of 18 and 65 2. Currently living in Colorado, New York, Montana, Texas, or Utah who have accessed VA care 3. Mild to moderate depressive symptoms, as determined by the PHQ-9, (score of 5-14) 4. Reliable access to a computer/tablet and the internet 5. Ability to provide informed consent Exclusion Criteria: 1. PHQ-9 score below 4 or 15 and above 2. Active alcohol or substance use disorder, excluding Cannabis dependence, as determined by screening or electronic medical record 3. Identification of active psychosis or bipolar disorder, as determined via screening or electronic medical record 4. Severe cognitive impairment, as determined by screening or electronic medical record 5. Currently enrolled in/participating in other intervention research study

Contact & Investigator

Central Contact

Kelly A Stearns-Yoder, MA

✉ kelly.stearns@va.gov

📞 720-723-6477

Principal Investigator

Lisa A Brenner, PhD

PRINCIPAL INVESTIGATOR

VA Eastern Colorado Health Care System

Frequently Asked Questions

Who can join the NCT06375083 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 65 Years, studying Suicide. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

What phase is the NCT06375083 trial and what does that mean for participants?

Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.

Is NCT06375083 currently recruiting?

Yes, NCT06375083 is actively recruiting participants. Contact the research team at kelly.stearns@va.gov for enrollment information.

Where is the NCT06375083 trial being conducted?

This trial is being conducted at Aurora, United States.

Who is sponsoring the NCT06375083 clinical trial?

NCT06375083 is sponsored by VA Eastern Colorado Health Care System. The principal investigator is Lisa A Brenner, PhD at VA Eastern Colorado Health Care System. The trial plans to enroll 472 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology